Author Archives: donttradeourlivesaway

DIPP defers decision on issuance of compulsory licence for cancer drug Dasatinib

Source: Economic Times The department of industrial policy and promotion, or DIPP, has delayed a decision on issuing a compulsory licence for cancer drug Dasatinib by seeking fresh clarification from the health ministry early this week. Through compulsory licensing — … Continue reading

Posted in access to medicines, Compulsory Licensing, Indian Patent Law, Intellectual Property, Out of Cycle Review (OCR), patent, US pressure on India, USTR 301 report | Tagged , , , | Leave a comment

USTR Begins Special 301 Report Out-of-Cycle Review of India

Source: USTR Washington, DC – In the 2014 Special 301 Report published in April, USTR called for renewed and intensive engagement on intellectual property (IP) issues with the Government of India, announcing that the United States would “redouble our efforts … Continue reading

Posted in IPR Enforcement, IPR policy, Out of Cycle Review (OCR), US pressure on India, USTR 301 report | Tagged , | Leave a comment

Is India pulling the leg?

Source: The Asian Age The Modi government has abandoned the fig leaf of adherence to public health goals… The first salvo was fired by Nirmala Sitharaman, signalling prior to Mr Modi’s visit to the US that India was willing to … Continue reading

Posted in access to medicines, Compulsory Licensing, Generic drug, Hepatitis - C, IP Rights, IPR policy, Novartis Case, Out of Cycle Review (OCR), patent, Right to Health, Sec 3 (d), Sofosbuvir, TRIPS, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

Inside Views: USTR’s Investigations On IP Rights Against India: Is There A Tenable Case?

Source: Ip-Watch On 14th October, the US Trade Representative (USTR) began the out-of-cycle review (OCR) of India’s intellectual property (IP) laws, the mandate which it gave itself in the 2014 Special 301 Report. Like several years in the past, the … Continue reading

Posted in access to medicines, Compulsory Licensing, Innovation, Intellectual Property, Novartis Case, Out of Cycle Review (OCR), patent, TRIPS, US India BIT, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

Egypt starts distributing Hepatitis C drug

Ahram Online , Thursday 16 Oct 2014 Egypt has started distributing Sovaldi, a drug for treating Hepatitis C. Health Minister Adel Adawi announced at a press conference on Thursday that a new national plan was underway for the prevention of … Continue reading

Posted in Drug Pricing, Hepatitis - C | Tagged , | Leave a comment

Investment: UN Rapporteur on right to health call for review of investment treaties

Source: TWN 17 Oct 2014 New Delhi, 13 October (K M Gopakumar) – Investment treaties should be reviewed to ensure that States have the right to make changes in their laws and policies to further human rights regardless of the … Continue reading

Posted in FTAs, Investment treaties, investor state dispute | Leave a comment

FDA Changes Policy Hours Before Approvals, Giving Companies Gift Potentially Worth Billions

Source: Posted 13 October 2014 By Alexander Gaffney, RAC Source: The Regulatory Affairs Professionals Society (RAPS) On Friday, two companies were the lucky recipients of gifts never before given by the US Food and Drug Administration (FDA)—gifts potentially worth millions, if … Continue reading

Posted in data exclusivity, Hepatitis - C | Leave a comment